Amador PC, López VJL, Herrera CJ, Tamariz HE, De la Torre RFE, Barriga AF, Mendoza LLD

Language: Spanish
References: 12
Page:
PDF size: 195.29 Kb.

ABSTRACT

Objective. The HPV infection has increased in the last 20 years and the highest prevalence rates are in adolescents and young women. The objective of this study was to determine the prevalence and distribution of HPV high-risk in women between 25 and 34 with abnormal cytology result.
Material and methods. We performed an observational, transversal, descriptive and clinical study, including 84 patients of 25-34 years old, with abnormal cytology results that had been tested with genotyping of 14 genotypes of human papillomavirus (HPV) high cancer risk by Chain Reaction (PCR) with COBAS 4800 system.
Results. The results where 15 (17.85%), women with cervical squamous atypia (ASC-US), 64 (76.35%) with low-grade intraepithelial lesion (LSIL), 4 (4.7%) with High Grade Intraepithelial Lesion (HSIL ) and 1 (1.1%) with Atypical Glandular Cells (AGC). For genotyping results was obtained as follows: 66 cases (78.5%) were positive for the panel or "pool" of high risk (12 high-risk genotypes), six were positive for HPV-16 (7.14% ), five panel positive for High Risk (HR) plus HPV-16 (5.95%), three were positive for HPV-18 (3.5%) and four cases were negative (4.76%). By correlating cytological abnormalities with HPV type, it was found that of the 15 ASC-US, 13 were positive for HR panel and 2 were negative. Of the 64 LSIL: 51 were positive for HR panel, 6 positive for HPV-16, HPV-positive 18, 2 HR-positive pool of more HPV-16 and 2 negative. Of the 4 HSIL, 1 was positive pool and 3 HR, and pool HR more positive HPV-16. The present patient was positive AGC AR panel.
Conclusions. The prevalence of high-risk oncogenic HPV is high (95%) in young women with abnormal cytology. This study shows that infection with multiple HPV types ("pool" 12 genotypes) was found in 78.57% of cases, while genotypes 16 and 18 was found in 16.66% of abnormal smears.

REFERENCES

1. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117:S5- 10.

2. Sam-Soto S, Ortiz de la Peña-Carranza A, Lira – Plascencia J. Virus del papiloma humano y

3. adolescencia. Ginecol Obstet Mex 2011;79(4):214- 224.

4. Apgar BS, Brotzman GL, Spitzer M. Colposcopia Principios y Práctica, El Sevier Saunders, 2ª edición, 2009, 21-29.

5. Human Papillomavirus: HPV information for clinicians. Centers for Disease Control and Prevention, 2007, 1-36.

6. Boch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cáncer. J Clin Pathol 2002; 55:244-265.

7. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervico-vaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.

8. Ronco G, Giordi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger tan 35 years: Results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7: 547-555.

9. Lazcano-Ponce E. Epidemiology of HPV infection among mexican women with normal cervical cytology. Int. J Cancer: 2001;91: 412-420.

10. Twiggs LB, Hopkins M. High-Risk HPV DNA testing and HPV-16/18 Genotyping: what is the clinical aplication? J Low Genit Tract Dis 2011;15:224-230

11. Mateos ML, Chacón de Antonio J, Rodríguez- Domínguez M, et al. Evaluación de un sistema de PCR a tiempo real (cobas 4800) para la detección separada de los genotipos 16 y 18 y otros genotipos de alto riesgo del virus del papiloma humano en la prevención del cáncer cervical. Enfer Infecc Microbiol Clin. 2011;29(6):411-414.

12. Maynard MH, duarte Franco E: Rodríguez J, Stephen DW, Hanley J, Ferenczy A, et al. For the Canadian Cervical Cancer Screening Trial Study Group. Human Papillomavirus DNA versus Papanicolaou screening tests for cervical cáncer. N Engl J Med. 2007; 357:1579-88. H.R.